Skip to content

Study · Randomized controlled trial · n = 87 · 2019

6 results

EFFICACY AND SAFETY OF IDEGLIRA IN OLDER PATIENTS WITH TYPE 2 DIABETES.

Lingvay I, Handelsman Y, Linjawi S, Vilsbøll T, Halladin N, Ranc K, Liebl A

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists1 Nov 2018Cited by 7 (Europe PMC)

PMID30383495 (opens in a new tab)DOI10.4158/ep-2018-0284 (opens in a new tab)PepBankPUB-30383495
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients aged 65 years or older with type 2 diabetes, insulin degludec/liraglutide lowered HbA1c more than insulin degludec alone (DUAL II).

    In plain wordsIn people aged 65 or older with type 2 diabetes, adding liraglutide to insulin degludec lowered HbA1c more than insulin degludec alone.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change in DUAL II versus insulin degludec
    Study

    n = 87

    Comparator
    Insulin degludec
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Measurements

    HbA1c estimated treatment difference
    −1%
    DUAL II, aged 65 years or older

    Source sentences

    Summary
    In patients ≥65 years, hemoglobin A1C decreased to a greater extent with IDegLira than with comparators (estimated treatment differences, -1.0% [-1.5; -0.6]95% confidence interval [CI], -0.8% [-1.0; -0.5]95% CI, and -0.9% [-1.3; -0.6]95%CI) for DUAL II, V, and III, respectively; all P<.001).
    2 context sentences
    Summary · context
    A post hoc analysis compared results of patients aged ≥65 versus <65 years from DUAL II, III, and V.
    Summary · context
    Patients were randomized to IDegLira or insulin degludec (DUAL II), IDegLira or unchanged glucagon-like peptide 1-receptor agonist (GLP-1RA) (DUAL III), or IDegLira or IGlar U100 (DUAL V).
  2. 02HumanRandomized controlled trialSafety outcome

    In patients aged 65 years or older with type 2 diabetes, the hypoglycaemia rate with insulin degludec/liraglutide did not differ significantly from insulin degludec alone (DUAL II).

    In plain wordsIn people aged 65 or older with type 2 diabetes, low blood sugar rates did not differ significantly from insulin degludec alone.

    Peptide
    Liraglutide
    Outcome
    No significant changeHypoglycaemia rate in DUAL II versus insulin degludec
    Study

    n = 87

    Comparator
    Insulin degludec
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Measurements

    Hypoglycaemia rate ratio
    0.5 ratio
    DUAL II

    Source sentences

    Summary
    Hypoglycemia rates were lower with IDegLira versus basal insulin and higher versus unchanged GLP-1RA (estimated rate ratios, 0.5 [0.2; 1.6]95% CI [ P = .242]; 0.3 [0.1; 0.5]95% CI [ P<.001], and 11.8 [3.3; 42.8]95% CI [ P<.001] for DUAL II, V, and III, respectively).
    2 context sentences
    Summary · context
    A post hoc analysis compared results of patients aged ≥65 versus <65 years from DUAL II, III, and V.
    Summary · context
    Patients were randomized to IDegLira or insulin degludec (DUAL II), IDegLira or unchanged glucagon-like peptide 1-receptor agonist (GLP-1RA) (DUAL III), or IDegLira or IGlar U100 (DUAL V).

Studies that did not test the peptide alone4

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 03HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In patients aged 65 years or older with type 2 diabetes, the fixed combination insulin degludec/liraglutide lowered HbA1c more than insulin glargine U100 (DUAL V).

    In plain wordsIn people aged 65 or older with type 2 diabetes, the insulin degludec and liraglutide combination lowered HbA1c more than insulin glargine.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change in DUAL V versus insulin glargine
    Study

    n = 145

    Comparator
    Insulin glargine U100
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    HbA1c estimated treatment difference
    −0.8%
    DUAL V, aged 65 years or older

    Source sentences

    Summary
    In patients ≥65 years, hemoglobin A1C decreased to a greater extent with IDegLira than with comparators (estimated treatment differences, -1.0% [-1.5; -0.6]95% confidence interval [CI], -0.8% [-1.0; -0.5]95% CI, and -0.9% [-1.3; -0.6]95%CI) for DUAL II, V, and III, respectively; all P<.001).
    2 context sentences
    Summary · context
    A post hoc analysis compared results of patients aged ≥65 versus <65 years from DUAL II, III, and V.
    Summary · context
    Patients were randomized to IDegLira or insulin degludec (DUAL II), IDegLira or unchanged glucagon-like peptide 1-receptor agonist (GLP-1RA) (DUAL III), or IDegLira or IGlar U100 (DUAL V).

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 04HumanNot a test of Liraglutide aloneRandomized controlled trialSafety outcome

    In patients aged 65 years or older with type 2 diabetes, the fixed combination insulin degludec/liraglutide had a lower hypoglycaemia rate than insulin glargine U100 (DUAL V).

    In plain wordsIn people aged 65 or older with type 2 diabetes, low blood sugar was less common with the combination than with insulin glargine.

    Peptide
    Liraglutide
    Outcome
    DecreaseHypoglycaemia rate in DUAL V versus insulin glargine
    Study

    n = 145

    Comparator
    Insulin glargine U100
    Outcome group
    Adverse events · Metabolic and weight

    Measurements

    Hypoglycaemia rate ratio
    0.3 ratio
    DUAL V

    Source sentences

    Summary
    Hypoglycemia rates were lower with IDegLira versus basal insulin and higher versus unchanged GLP-1RA (estimated rate ratios, 0.5 [0.2; 1.6]95% CI [ P = .242]; 0.3 [0.1; 0.5]95% CI [ P<.001], and 11.8 [3.3; 42.8]95% CI [ P<.001] for DUAL II, V, and III, respectively).
    2 context sentences
    Summary · context
    A post hoc analysis compared results of patients aged ≥65 versus <65 years from DUAL II, III, and V.
    Summary · context
    Patients were randomized to IDegLira or insulin degludec (DUAL II), IDegLira or unchanged glucagon-like peptide 1-receptor agonist (GLP-1RA) (DUAL III), or IDegLira or IGlar U100 (DUAL V).

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 05HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In patients aged 65 years or older with type 2 diabetes, the fixed combination insulin degludec/liraglutide lowered HbA1c more than an unchanged GLP-1 receptor agonist (DUAL III).

    In plain wordsIn people aged 65 or older with type 2 diabetes, the insulin degludec and liraglutide combination lowered HbA1c more than an unchanged GLP-1 drug.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change in DUAL III versus unchanged GLP-1 receptor agonist
    Study

    n = 112

    Comparator
    Unchanged GLP-1 receptor agonist
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    HbA1c estimated treatment difference
    −0.9%
    DUAL III, aged 65 years or older

    Source sentences

    Summary
    In patients ≥65 years, hemoglobin A1C decreased to a greater extent with IDegLira than with comparators (estimated treatment differences, -1.0% [-1.5; -0.6]95% confidence interval [CI], -0.8% [-1.0; -0.5]95% CI, and -0.9% [-1.3; -0.6]95%CI) for DUAL II, V, and III, respectively; all P<.001).
    2 context sentences
    Summary · context
    A post hoc analysis compared results of patients aged ≥65 versus <65 years from DUAL II, III, and V.
    Summary · context
    Patients were randomized to IDegLira or insulin degludec (DUAL II), IDegLira or unchanged glucagon-like peptide 1-receptor agonist (GLP-1RA) (DUAL III), or IDegLira or IGlar U100 (DUAL V).

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 06HumanNot a test of Liraglutide aloneRandomized controlled trialSafety outcome

    In patients aged 65 years or older with type 2 diabetes, the fixed combination insulin degludec/liraglutide had a higher hypoglycaemia rate than an unchanged GLP-1 receptor agonist (DUAL III).

    In plain wordsIn people aged 65 or older with type 2 diabetes, low blood sugar was more common with the combination than with an unchanged GLP-1 drug.

    Peptide
    Liraglutide
    Outcome
    IncreaseHypoglycaemia rate in DUAL III versus unchanged GLP-1 receptor agonist
    Study

    n = 112

    Comparator
    Unchanged GLP-1 receptor agonist
    Outcome group
    Adverse events · Metabolic and weight

    Measurements

    Hypoglycaemia rate ratio
    11.8 ratio
    DUAL III

    Source sentences

    Summary
    Hypoglycemia rates were lower with IDegLira versus basal insulin and higher versus unchanged GLP-1RA (estimated rate ratios, 0.5 [0.2; 1.6]95% CI [ P = .242]; 0.3 [0.1; 0.5]95% CI [ P<.001], and 11.8 [3.3; 42.8]95% CI [ P<.001] for DUAL II, V, and III, respectively).
    2 context sentences
    Summary · context
    A post hoc analysis compared results of patients aged ≥65 versus <65 years from DUAL II, III, and V.
    Summary · context
    Patients were randomized to IDegLira or insulin degludec (DUAL II), IDegLira or unchanged glucagon-like peptide 1-receptor agonist (GLP-1RA) (DUAL III), or IDegLira or IGlar U100 (DUAL V).

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials3

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

3 trials · 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01952145

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus

Novo Nordisk A/Sn = 55720 Sept 2013 to 4 Nov 2014

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 3 Jan 2019
CompletedPhase 3Results postedNCT01676116

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy

Novo Nordisk A/Sn = 43829 Aug 2012 to 11 Mar 2014

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 3 Jan 2019
CompletedPhase 3Results postedNCT01392573

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 41328 Nov 2011 to 4 Oct 2012

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 3 Jan 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.